Home >> Research >> Programmes >> Cardiovascular diseases >> Funding and Impact - Cardiovascular Diseases

Funding and Impact - Cardiovascular Diseases

Impact of previous awards on healthcare

  • Dr Pier Lambiase confirms the role of genetic testing in sudden arrhythmic death syndrome In this investigation based on the recognised capability of molecular autopsy, cardiologists were able to utilise full exome sequencing to identify mutations in ion channel and cardiomyopathy genes responsible for sudden cardiac death. The study has important implications in informing genetic screening of sudden arrhythmic death syndrome families.

  • Promising new treatment found for respiratory syndrome in study led by Dr Geoff Bellingan Led by UCLH, the Faron trial of interferon beta in acute respiratory distress syndrome (ARDS) - a phase 1/2 study across 9 centres - has successfully demonstrated excitingly low mortality of <10% for the treated patients. A parallel group not treated had a mortality of over 30%. Read more

  • UCLH team leads second expedition to Everest to investigate critical care - Building on the success of Xtreme Everest 1 (2007), Xtreme Everest 2 has now completed in collaboration with Southampton & Duke University Medical Centre providing a rich dataset on human adaptation to hypoxia and insight into treating intensive care patients. Read more

  • Study by Professor Rachel Batterham reveals how ‘obesity gene’ triggers weight gain This collaboration led by UCLH and scientists from UCL, MRC and Kings College London, has shown that people with the obesity-risk FTO variant have higher circulating levels of the ‘hunger hormone’ ghrelin in their blood, revealing why people with a variation of the FTO gene are 70% more likely to become obese. Read more